
Avient Corp (AVNT) Stock Forecast & Price Target
Avient Corp (AVNT) Analyst Ratings
Bulls say
Avient Corp has experienced a 5% increase in organic sales, with its healthcare segment demonstrating particularly strong performance, achieving a 14% year-over-year growth in the first half of fiscal year 2025 and sustaining double-digit growth for six consecutive quarters. Additionally, four out of nine end markets, which collectively represent 40% of Avient's sales, are showing growth this year, contributing to an overall organic sales increase of approximately 2% for 2025. Despite anticipated negative growth in the consumer end market, the company's diversified product portfolio and strong revenue generation from key sectors indicate a positive financial outlook for Avient.
Bears say
Avient Corp has experienced negative organic sales growth, with a decline of approximately 2% in the first quarter of 2024 followed by fluctuations in growth rates in subsequent quarters, raising concerns about its revenue stability. A weakening demand for chemicals since mid-2025 poses further risks, as recent assessments indicate potential declines in volume for the latter half of 2025. While a depreciating dollar could provide some support, the overarching financial metrics suggest a concerning trend that may impact Avient's future performance negatively.
This aggregate rating is based on analysts' research of Avient Corp and is not a guaranteed prediction by Public.com or investment advice.
Avient Corp (AVNT) Analyst Forecast & Price Prediction
Start investing in Avient Corp (AVNT)
Order type
Buy in
Order amount
Est. shares
0 shares